Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03117920 | A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer(MinPAC) | completed | Phase 2 | 19 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 |
| clinicaltrials |
| NCT01959672 | Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer | completed | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03611556 | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | completed | Phase 1 / Phase 2 | 213 | MedImmune LLCINDUSTRY | 4 | Oct 3, 2023 | clinicaltrials |
| NCT05906615 | Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis(LIDOPAN) | completed | Phase 2 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT00089024 | Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 29 | University of NebraskaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02767557 | Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients(PACTO) | completed | Phase 2 | 147 | Herlev HospitalOTHER | 2 | Sep 22, 2023 | clinicaltrials |
| NCT02866383 | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients(CheckPAC) | completed | Phase 2 | 160 | Herlev HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02427841 | Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT01470417 | Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma(GAIN-1) | completed | Phase 2 | 10 | University of FloridaOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04953962 | Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer | completed | Phase 2 | 36 | CanBas Co. Ltd.INDUSTRY | 1 | Aug 15, 2023 | clinicaltrials |
| NCT00161213 | Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer | completed | Phase 2 | 44 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT01726582 | Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") | completed | Phase 2 | 229 | Medical College of WisconsinOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00265876 | AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02324543 | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT00965718 | Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer | completed | Phase 2 | 20 | GC Cell CorporationINDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT00042939 | Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 94 | Eastern Cooperative Oncology GroupNETWORK | 0 | Jul 6, 2023 | clinicaltrials |
| NCT00427349 | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02775695 | Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer | completed | Phase 2 | 12 | Medical College of WisconsinOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01684098 | Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor | completed | Phase 2 | 40 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT00003810 | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00049348 | Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer(NEONAX) | completed | Phase 2 | 127 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02042378 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | completed | Phase 2 | 19 | pharmaand GmbHINDUSTRY | 2 | Jun 13, 2023 | clinicaltrials |
| NCT00202800 | Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | Corewell Health WestOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT01845337 | Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine(TOFFEE) | completed | Phase 2 | 59 | University of EdinburghOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT02578732 | FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 28 | Brown UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02511223 | Efficacy and Safety of PARPi to Treat Pancreatic Cancer(10) | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer(THERGAP-02) | completed | Phase 2 | 68 | University Hospital, ToulouseOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT02707159 | Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients(PACT-ACT-v6) | completed | Phase 2 | 70 | Helse Stavanger HFOTHER_GOV | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02210559 | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 37 | Kyntra BioINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT02028806 | mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT01647828 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer(ALPINE) | completed | Phase 1 / Phase 2 | 217 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03977272 | Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer | completed | Phase 2 | 110 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT01939665 | PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma(PANFIRE) | completed | Phase 1 / Phase 2 | 50 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02428270 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT01845805 | Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine) | completed | Phase 2 | 49 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02651987 | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg(CLARINET FORTE) | completed | Phase 2 | 99 | IpsenINDUSTRY | 10 | Oct 3, 2022 | clinicaltrials |
| NCT03158779 | Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 45 | Istituto Clinico HumanitasOTHER | 1 | Sep 15, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 18, 2023source: clinicaltrials